Laura Huppert, MD(@laura_huppert) 's Twitter Profileg
Laura Huppert, MD

@laura_huppert

Breast oncologist @UCSF | Interested in breast cancer clinical/translational research, med ed | Author of Huppert’s Notes | Tweets my own

ID:1255950517471023104

calendar_today30-04-2020 20:02:01

249 Tweets

1,3K Followers

670 Following

Alejandro Rios(@alriho1) 's Twitter Profile Photo

Our latest article on Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer, just published ascopubs.org/doi/10.1200/JC…
Erin Cobain Laura Huppert, MD Peter Beitsch Hope Rugo Dr. Laura Esserman Laura VAN T VEER YaleBreastCancer

account_circle
Laura Huppert, MD(@laura_huppert) 's Twitter Profile Photo

So incredibly well-deserved Hope Rugo!!! Your dedication to patients is unparalleled & your contributions to practice-changing clinical research are truly exceptional. And on a personal note, thank you for being the best mentor EVER! You are amazing! UCSF Helen Diller Family Comprehensive Cancer Ctr

account_circle
Kathryn Gallaway, MD(@KE_Gallaway) 's Twitter Profile Photo

Fantastic panel diving deep into the data for SG and Dato-DXd in breast cancer, including a flurry of trials bringing these agents into the frontine metastatic and neoadjuvant space.

Will traditional chemo become a thing of the past?

Fantastic panel diving deep into the data for SG and Dato-DXd in breast cancer, including a flurry of trials bringing these agents into the frontine metastatic and neoadjuvant space. Will traditional chemo become a thing of the past? #DAVAVictoriaADCs
account_circle
OncLive.com(@OncLive) 's Twitter Profile Photo

Laura Huppert, MD from UCSF Helen Diller Family Comprehensive Cancer Ctr summarizes systemic therapy for early-stage TNBC with a roadmap of current treatment algorithm and discussion of future directions - opportunities to deescalate/escalate therapy and trials for neoadj and/or adj ADCs under investigation!

@laura_huppert from @UCSFCancer summarizes systemic therapy for early-stage TNBC with a roadmap of current treatment algorithm and discussion of future directions - opportunities to deescalate/escalate therapy and trials for neoadj and/or adj ADCs under investigation! #MBCC24
account_circle
Laura Huppert, MD(@laura_huppert) 's Twitter Profile Photo

Met the wonderful Paolo Tarantino at Miami Breast two years ago… so fun to be back at together again and continuing our selfie collection! ☀️

Met the wonderful @PTarantinoMD at Miami Breast two years ago… so fun to be back at #MBCC24 together again and continuing our selfie collection! ☀️
account_circle
OncLive.com(@OncLive) 's Twitter Profile Photo

Tune in tomorrow for a day of live coverage, beginning with timely updates from Laura Huppert, MD of UCSF Helen Diller Family Comprehensive Cancer Ctr, who is taking over the OncLive Twitter account to spotlight key updates in the breast cancer space! PER

Tune in tomorrow for a day of live #MBCC24 coverage, beginning with timely updates from @laura_huppert of @UCSFCancer, who is taking over the OncLive Twitter account to spotlight key updates in the breast cancer space! @gotoPER #bcsm #oncology
account_circle
ANCO(@ANCO_News) 's Twitter Profile Photo

We are 10 days away from Best of SABCS-West with Hope Rugo! Will you be joining us at the Claremont Hotel Berkeley? A special discounted registration rate of $35 is offered to ANCO members.
Register now: bit.ly/3HnBUdz

We are 10 days away from Best of SABCS-West with @hoperugo! Will you be joining us at the Claremont Hotel Berkeley? A special discounted registration rate of $35 is offered to ANCO members. Register now: bit.ly/3HnBUdz #ANCO #BestofSABCSWest2024
account_circle
Laura Huppert, MD(@laura_huppert) 's Twitter Profile Photo

Our retrospective multi-center registry of ADC-after-ADC in HER2-low MBC. Most pts have longer PFS on ADC1 vs 2, but not always (so worth trying!) Tx for highlighting VuMedi & for the awesome collaboration Hope Rugo Reshma Mahtani D Idossa, MD Ruta Rao Sarah Premji & others!

account_circle
Laura Huppert, MD(@laura_huppert) 's Twitter Profile Photo

Beautiful presentation by ⭐️ UCSF Helen Diller Family Comprehensive Cancer Ctr fellow Saya Jacob about incidence of delayed IRAEs. Retrospective analysis of 300+ pt- 25% rate delayed toxicity (>90d post-ICI start) & 7.5% post-tx, mostly endocrine. Prior early IRAE= ⬆️ late IRAEs. Need to keep monitoring post ICI!

Beautiful presentation by ⭐️ @UCSFCancer fellow @SayaJacob3 about incidence of delayed IRAEs. Retrospective analysis of 300+ pt- 25% rate delayed toxicity (>90d post-ICI start) & 7.5% post-tx, mostly endocrine. Prior early IRAE= ⬆️ late IRAEs. Need to keep monitoring post ICI!
account_circle
Dr Sarah Sammons(@drsarahsam) 's Twitter Profile Photo

Incidence of brain metastases in 17,000 pts with MBC per subtype.

1) Incidence increases per line, except HR-, HER2+ which is early event
2) HER2Low, no impact on BM incidence.

Incidence of brain metastases in 17,000 pts with MBC per subtype. 1) Incidence increases per line, except HR-, HER2+ which is early event 2) HER2Low, no impact on BM incidence.
account_circle
Erika Hamilton, MD(@ErikaHamilton9) 's Twitter Profile Photo

Some fantastic points in the 1st brain mets discussion this am.

🔺LMD is a high unmet need

🔺we are underutilizing real world data for learning

🔺CSF biomarkers may be particularly important as we see more patients with brain only disease

SABCS

Some fantastic points in the 1st brain mets discussion this am. 🔺LMD is a high unmet need 🔺we are underutilizing real world data for learning 🔺CSF biomarkers may be particularly important as we see more patients with brain only disease #SABCS23 @SABCSSanAntonio #bcsm
account_circle
Erika Hamilton, MD(@ErikaHamilton9) 's Twitter Profile Photo

Laura Huppert, MD presents translational analysis of leptomemingeal disease

57% of LMD had actionable alterations among those HR+

Also observed heterogeneity between CSF, blood, and tumor tissue

SABCS

@laura_huppert presents translational analysis of leptomemingeal disease 57% of LMD had actionable alterations among those HR+ Also observed heterogeneity between CSF, blood, and tumor tissue #SABCS23 @SABCSSanAntonio
account_circle
Nancy Lin, MD(@nlinmd) 's Twitter Profile Photo

What do real-world data say about ADC sequencing and resistance? Dr. Ana Garrido-Castro Dana-Farber’s Breast Oncology Center beautifully summarizes the existing data and stresses the importance of prospective trials and translational science to move the field further forward.

What do real-world data say about ADC sequencing and resistance? Dr. Ana Garrido-Castro @DFCI_BreastOnc beautifully summarizes the existing data and stresses the importance of prospective trials and translational science to move the field further forward. #SABCS23
account_circle